

## List of references:

1. Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., ... & Arslanian, S. (2022). Once-weekly semaglutide in adolescents with obesity. *New England Journal of Medicine*, 387(24), 2245-2257.
2. Chao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019). Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology. *Obesity*, 27(12), 2005-2010.
3. Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020). Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. *Obesity*, 28(3), 529-536.
4. Kolotkin, R. L., Smolarz, B. G., Meincke, H. H., & Fujioka, K. (2018). Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. *Clinical obesity*, 8(1), 1-10.
5. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *Jama*, 325(14), 1414-1425.
6. Lundgren, J. R., Janus, C., Jensen, S. B., Juhl, C. R., Olsen, L. M., Christensen, R. M., ... & Torekov, S. S. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. *New England Journal of Medicine*, 384(18), 1719-1730.
7. Farr, O. M., Upadhyay, J., Rutagengwa, C., DiPrisco, B., Ranta, Z., Adra, A., ... & Mantzoros, C. S. (2019). Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. *Diabetes, Obesity and Metabolism*, 21(11), 2459-2464.
8. Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., ... & Yoon, K. H. (2019). Body weight management and safety with efglenatide in adults without diabetes: a phase II randomized study. *Diabetes, Obesity and Metabolism*, 21(11), 2429-2439.
9. Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., ... & Mignot, E. (2016). Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *International journal of obesity*, 40(8), 1310-1319.
10. Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., ... & Krakoff, J. (2018). Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. *Metabolism*, 85, 116-125.
11. Chao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019). Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day. *Clinical obesity*, 9(6), e12340.
12. Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., ... & Astrup, A. (2014). Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. *International journal of obesity*, 38(5), 689-697.
13. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *International journal of obesity*, 37(11), 1443-1451.
14. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*, 384(11), 989-1002.

15. Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017). Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. *Diabetes, Obesity and Metabolism*, 19(9), 1276-1288.
16. Utzschneider, K. M., Ehrmann, D. A., Arslanian, S. A., Barendolts, E., Buchanan, T. A., Caprio, S., ... & RISE Consortium. (2022). Weight loss and  $\beta$ -cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. *Obesity*, 30(8), 1579-1588.
17. Rodgers, M., Migdal, A. L., Rodríguez, T. G., Chen, Z. Z., Nath, A. K., Gerszten, R. E., ... & Dushay, J. (2021). Weight loss outcomes among early high responders to exenatide treatment: A randomized, placebo controlled study in overweight and obese women. *Frontiers in Endocrinology*, 12, 742873.
18. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., ... & STEP 3 Investigators. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. *Jama*, 325(14), 1403-1413.
19. Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., ... & Tronieri, J. S. (2019). Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. *Obesity*, 27(1), 75-86.
20. Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., ... & Kosiborod, M. N. (2023). Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. *Nature medicine*, 29(9), 2358-2365.
21. Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., ... & NN8022-1922 Study Group. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. *Jama*, 314(7), 687-699.
22. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *The Lancet*, 397(10278), 971-984.
23. Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satyrganova, A., ... & Mosenzon, O. (2020). Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. *Diabetes care*, 43(5), 1085-1093.
24. Gudbergesen, H., Overgaard, A., Henriksen, M., Wæhrens, E. E., Bliddal, H., Christensen, R., ... & Kristensen, L. E. (2021). Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. *The American journal of clinical nutrition*, 113(2), 314-323.
25. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*, 387(3), 205-216.
26. Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., ... & Lim, S. (2022). Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. *The Lancet Diabetes & Endocrinology*, 10(3), 193-206.
27. Kim, S. H., Abbasi, F., Lamendola, C., Liu, A., Ariel, D., Schaaf, P., ... & Reaven, G. (2013). Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. *Diabetes care*, 36(10), 3276-3282.
28. Le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C., Van Gaal, L., ... & Farrell, J. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *The Lancet*, 389(10077), 1399-1409.

29. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. *New England Journal of Medicine*, 389(24), 2221-2232.
30. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 375(4), 311-322.
31. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *New England Journal of Medicine*, 373(1), 11-22.
32. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *Jama*, 325(14), 1414-1425.
33. Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Baidal, J. A. W., Kelly, A. S., & Hur, C. (2023). Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents. *JAMA Network Open*, 6(8), e2329178-e2329178.
34. Saumoy, M., Gandhi, D., Buller, S., Patel, S., Schneider, Y., Cote, G., ... & Sharaiha, R. Z. (2023). Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. *Gut*, 72(12), 2250-2259.
35. Lumbreras, A. G., Tan, M. S., Villa-Zapata, L., Ilham, S., Earl, J. C., & Malone, D. C. (2023). Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. *Nutrition, Metabolism and Cardiovascular Diseases*, 33(6), 1268-1276.
36. Nuijten, M., Dainelli, L., Rasouli, B., Araujo Torres, K., Perugini, M., & Marczewska, A. (2021). A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective. *Diabetes, Metabolic Syndrome and Obesity*, 3147-3160.
37. Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., ... & Hur, C. (2020). The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. *Obesity Science & Practice*, 6(2), 162-170.
38. Nuijten, M., Marczewska, A., Araujo Torres, K., Rasouli, B., & Perugini, M. (2018). A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States. *Journal of Medical Economics*, 21(9), 835-844.